This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Takeuchi, H. Articles by Hoon, D. S. B. Search for Related Content PubMed PubMed Citation Articles by Takeuchi, H. Articles by Hoon, D. S. B.

Expression of Differentiation Melanoma-associated Antigen Genes Is Associated with Favorable Disease Outcome in Advanced-Stage Melanomas¹

Department of Molecular Oncology [H. T., C. K., D. S. B. H.], Division of Biostatistics [H-J. W.], and John Wayne Cancer Institute [D. L. M.], Saint John’s Health Center, Santa Monica, California 90404

Cutaneous melanomas have been found to express several immunogenic differentiation melanoma-associated antigens (MAAs) that have been suggested to play an important role in disease outcome. Adaptive host immunity to MAAs has shown some level of control on melanoma progression. To date, there has been no definitive report correlating the level of differentiated MAAs gene expression in melanomas with overall disease outcome. Metastasis of melanoma to distant visceral organ sites usually indicates a survival of less than 1 year; however, a subset of patients who undergo cytoreductive surgery of distant metastases survive for a longer period. We hypothesized that the gene expression level of differentiation MAAs in metastatic melanoma (AJCC stage IV) lesions would be predictive of survival. We focused on three known differentiation MAAs: tyrosinase (TYR), TYR-related protein 2 (TRP-2), and melanoma antigen recognized by T cells 1 (MART-1); all three of them are known to induce immune responses in melanoma patients and are frequently expressed in melanomas. A quantitative reverse-transcriptase RealTime PCR (qRT) assay was developed for these MAAs to assess mRNA expression in metastatic melanoma tumors obtained from cytoreductive surgery of AJCC stage IV melanoma patients (n = 35). Patients were followed up for over 60 months. There was a variation in mRNA copy levels for individual MAAs in melanoma tumors. Elevated MAA mRNA copy levels of TYR and TRP-2 significantly (P < 0.03 and < 0.009, respectively) correlated with improved overall survival. Patients having at least one MAA expressed in their tumors had a significantly (P = 0.01) better overall survival (median 16 months). These studies demonstrate that levels of differentiated MAA mRNA expression of advanced-stage metastatic melanomas can be used as molecular predictive factors of disease outcome. The studies also imply that an assessment of melanoma tumor MAAs may provide a stratification factor targeted for active-specific immunotherapy.

This article has been cited by other articles:

				M. F.G. de Maat, C. J.H. van de Velde, N. Umetani, P. de Heer, H. Putter, A. Q. van Hoesel, G. A. Meijer, N. C. van Grieken, P. J.K. Kuppen, A. J. Bilchik, et al. Epigenetic Silencing of Cyclooxygenase-2 Affects Clinical Outcome in Gastric Cancer J. Clin. Oncol., November 1, 2007; 25(31): 4887 - 4894. [Abstract] [Full Text] [PDF]

				H. Takeuchi, N. C. Greep, D. S. B. Hoon, A. E. Giuliano, N. M. Hansen, N. Umetani, and F. R. Singer Hypermethylation of Adenosine Triphosphate-Binding Cassette Transporter Genes in Primary Hyperparathyroidism and Its Effect on Sestamibi Imaging J. Clin. Endocrinol. Metab., May 1, 2007; 92(5): 1785 - 1790. [Abstract] [Full Text] [PDF]

				M. Kono, I. S. Dunn, P. J. Durda, D. Butera, L. B. Rose, T. J. Haggerty, E. M. Benson, and J. T. Kurnick Role of the Mitogen-Activated Protein Kinase Signaling Pathway in the Regulation of Human Melanocytic Antigen Expression Mol. Cancer Res., October 1, 2006; 4(10): 779 - 792. [Abstract] [Full Text] [PDF]

				L.-M. Postovit, E. A. Seftor, R. E.B. Seftor, and M. J.C. Hendrix Influence of the Microenvironment on Melanoma Cell Fate Determination and Phenotype Cancer Res., August 15, 2006; 66(16): 7833 - 7836. [Abstract] [Full Text] [PDF]

				A. J. Miller and M. C. Mihm Jr. Melanoma. N. Engl. J. Med., July 6, 2006; 355(1): 51 - 65. [Full Text] [PDF]

				Y. Goto, Y. Matsuzaki, S. Kurihara, A. Shimizu, T. Okada, K. Yamamoto, H. Murata, M. Takata, H. Aburatani, D. S.B. Hoon, et al. A new melanoma antigen Fatty Acid-binding protein 7, involved in proliferation and invasion, is a potential target for immunotherapy and molecular target therapy. Cancer Res., April 15, 2006; 66(8): 4443 - 4449. [Abstract] [Full Text] [PDF]

				P. M. Kulesa, J. C. Kasemeier-Kulesa, J. M. Teddy, N. V. Margaryan, E. A. Seftor, R. E. B. Seftor, and M. J. C. Hendrix Reprogramming metastatic melanoma cells to assume a neural crest cell-like phenotype in an embryonic microenvironment PNAS, March 7, 2006; 103(10): 3752 - 3757. [Abstract] [Full Text] [PDF]

				L.-M. Postovit, E. A. Seftor, R. E.B. Seftor, and M. J.C. Hendrix A Three-Dimensional Model to Study the Epigenetic Effects Induced by the Microenvironment of Human Embryonic Stem Cells Stem Cells, March 1, 2006; 24(3): 501 - 505. [Abstract] [Full Text] [PDF]

				K. Koyanagi, S. J. O'Day, R. Gonzalez, K. Lewis, W. A. Robinson, T. T. Amatruda, C. Kuo, H.-J. Wang, R. Milford, D. L. Morton, et al. Microphthalmia Transcription Factor as a Molecular Marker for Circulating Tumor Cell Detection in Blood of Melanoma Patients Clin. Cancer Res., February 15, 2006; 12(4): 1137 - 1143. [Abstract] [Full Text] [PDF]

				E. A. Seftor, K. M. Brown, L. Chin, D. A. Kirschmann, W. W. Wheaton, A. Protopopov, B. Feng, Y. Balagurunathan, J. M. Trent, B. J. Nickoloff, et al. Epigenetic Transdifferentiation of Normal Melanocytes by a Metastatic Melanoma Microenvironment Cancer Res., November 15, 2005; 65(22): 10164 - 10169. [Abstract] [Full Text] [PDF]

				H. Takeuchi, J. Kim, A. Fujimoto, N. Umetani, T. Mori, A. Bilchik, R. Turner, A. Tran, C. Kuo, and D. S.B. Hoon X-Linked Inhibitor of Apoptosis Protein Expression Level in Colorectal Cancer Is Regulated by Hepatocyte Growth Factor/C-Met Pathway via Akt Signaling Clin. Cancer Res., November 1, 2005; 11(21): 7621 - 7628. [Abstract] [Full Text] [PDF]

				A. Paschen, M. Song, W. Osen, X. D. Nguyen, J. Mueller-Berghaus, D. Fink, N. Daniel, M. Donzeau, W. Nagel, H. Kropshofer, et al. Detection of Spontaneous CD4+ T-Cell Responses in Melanoma Patients against a Tyrosinase-Related Protein-2-Derived Epitope Identified in HLA-DRB1*0301 Transgenic Mice Clin. Cancer Res., July 15, 2005; 11(14): 5241 - 5247. [Abstract] [Full Text] [PDF]

				K. Koyanagi, C. Kuo, T. Nakagawa, T. Mori, H. Ueno, A. R. Lorico Jr, H.-J. Wang, E. Hseuh, S. J. O'Day, and D. S.B. Hoon Multimarker Quantitative Real-Time PCR Detection of Circulating Melanoma Cells in Peripheral Blood: Relation to Disease Stage in Melanoma Patients Clin. Chem., June 1, 2005; 51(6): 981 - 988. [Abstract] [Full Text] [PDF]

				S. Raja, J. Ching, L. Xi, S. J. Hughes, R. Chang, W. Wong, W. McMillan, W. E. Gooding, K. S. McCarty Jr, M. Chestney, et al. Technology for Automated, Rapid, and Quantitative PCR or Reverse Transcription-PCR Clinical Testing Clin. Chem., May 1, 2005; 51(5): 882 - 890. [Abstract] [Full Text] [PDF]

				T. Mori, J. Kim, T. Yamano, H. Takeuchi, S. Huang, N. Umetani, K. Koyanagi, and D. S.B. Hoon Epigenetic Up-regulation of C-C Chemokine Receptor 7 and C-X-C Chemokine Receptor 4 Expression in Melanoma Cells Cancer Res., March 1, 2005; 65(5): 1800 - 1807. [Abstract] [Full Text] [PDF]

				H. N. Abrahamsen, B. Sandahl Sorensen, E. Nexo, S. J. Hamilton-Dutoit, J. Larsen, and T. Steiniche Pathologic Assessment of Melanoma Sentinel Nodes: A Role for Molecular Analysis Using Quantitative Real-Time Reverse Transcription-PCR for MART-1 and Tyrosinase Messenger RNA Clin. Cancer Res., February 15, 2005; 11(4): 1425 - 1433. [Abstract] [Full Text] [PDF]

				K. K. Sra, M. Babb-Tarbox, S. Aboutalebi, P. Rady, G. L. Shipley, D. D. Dao, and S. K. Tyring Molecular Diagnosis of Cutaneous Diseases Arch Dermatol, February 1, 2005; 141(2): 225 - 241. [Abstract] [Full Text] [PDF]

				N. Umetani, H. Takeuchi, A. Fujimoto, M. Shinozaki, A. J. Bilchik, and D. S. B. Hoon Epigenetic Inactivation of ID4 in Colorectal Carcinomas Correlates with Poor Differentiation and Unfavorable Prognosis Clin. Cancer Res., November 15, 2004; 10(22): 7475 - 7483. [Abstract] [Full Text] [PDF]

				H. N. Abrahamsen, E. Nexo, T. Steiniche, S. J. Hamilton-Dutoit, and B. S. Sorensen Quantification of Melanoma mRNA Markers in Sentinel Nodes: Pre-Clinical Evaluation of a Single-Step Real-Time Reverse Transcriptase-Polymerase Chain Reaction Assay J. Mol. Diagn., August 1, 2004; 6(3): 253 - 259. [Abstract] [Full Text]

				K.-i. Yasumoto, H. Watabe, J. C. Valencia, T. Kushimoto, T. Kobayashi, E. Appella, and V. J. Hearing Epitope Mapping of the Melanosomal Matrix Protein gp100 (PMEL17): RAPID PROCESSING IN THE ENDOPLASMIC RETICULUM AND GLYCOSYLATION IN THE EARLY GOLGI COMPARTMENT J. Biol. Chem., July 2, 2004; 279(27): 28330 - 28338. [Abstract] [Full Text] [PDF]

				H. Takeuchi, D. L. Morton, C. Kuo, R. R. Turner, D. Elashoff, R. Elashoff, B. Taback, A. Fujimoto, and D. S.B. Hoon Prognostic Significance of Molecular Upstaging of Paraffin-Embedded Sentinel Lymph Nodes in Melanoma Patients J. Clin. Oncol., July 1, 2004; 22(13): 2671 - 2680. [Abstract] [Full Text] [PDF]

				H. Takeuchi, A. Fujimoto, M. Tanaka, T. Yamano, E. Hsueh, and D. S. B. Hoon CCL21 Chemokine Regulates Chemokine Receptor CCR7 Bearing Malignant Melanoma Cells Clin. Cancer Res., April 1, 2004; 10(7): 2351 - 2358. [Abstract] [Full Text] [PDF]

				A. Fujimoto, H. Takeuchi, B. Taback, E. C. Hsueh, D. Elashoff, D. L. Morton, and D. S. B. Hoon Allelic Imbalance of 12q22-23 Associated with APAF-1 Locus Correlates with Poor Disease Outcome in Cutaneous Melanoma Cancer Res., March 15, 2004; 64(6): 2245 - 2250. [Abstract] [Full Text] [PDF]

				H. Watabe, J. C. Valencia, K.-i. Yasumoto, T. Kushimoto, H. Ando, J. Muller, W. D. Vieira, M. Mizoguchi, E. Appella, and V. J. Hearing Regulation of Tyrosinase Processing and Trafficking by Organellar pH and by Proteasome Activity J. Biol. Chem., February 27, 2004; 279(9): 7971 - 7981. [Abstract] [Full Text] [PDF]

				A. J. Miller, J. Du, S. Rowan, C. L. Hershey, H. R. Widlund, and D. E. Fisher Transcriptional Regulation of the Melanoma Prognostic Marker Melastatin (TRPM1) by MITF in Melanocytes and Melanoma Cancer Res., January 15, 2004; 64(2): 509 - 516. [Abstract] [Full Text] [PDF]

				J. Szenajch, B. Jasinski, A. Synowiec, J. Kulik, M. Chomicka, J. Struzyna, Z. Nowecki, P. Rutkowski, W. Ruka, W. Kupsc, et al. Prognostic Value of Multiple Reverse Transcription-PCR Tyrosinase Testing for Circulating Neoplastic Cells in Malignant Melanoma Clin. Chem., September 1, 2003; 49(9): 1450 - 1457. [Abstract] [Full Text] [PDF]